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Abstract: In order to test the for existence of
a possible effect during hemodialysis we investigated glutathione and related enzymes
before and after dialysis of 36 patients (20
M/16 F) with chronic renal failure (CRF). 25
healthy person (15 M/10F) served as controls. Erythrocyte reduced glutathione (GSH)
concentrations, glucose –6- phosphate dehydrogenase (G-6-PD), glutathione peroxidase
(GPX) activities and plasma GPX activities
were significantly decreased in patients
(p<0.01). These levels were significantly increased with dialysis (p<0.01) but were still
lower than in controls. Predialysis plasma
GSH levels of patients were not significantly
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Introduction
Glutathione is the most abundant low molecular
weight thiol-containing containing comopund in living
cells. Its reduced form (GSH) contributes to the viability of erythrocytes by stabilizing thiol groups of
membrane enzymes and hemoglobin, and by acting as
a reducing agent for hydroperoxides and free radicals,
thus protecting the red cells against oxidative damage
(1). Intracellular GSH is converted into oxidized glutathione (GSSG) by glutathione peroxidase (GPX),
which catalyzes the reduction of peroxides (2). Selenium is an essential component of the GPX and GPX
activity is related to the blood selenium (Se) level (3).
Glucose-6-phosphate dehydrogenase (G-6-PD) as a
source of NADPH guarantees the reduction of GSSG
to GSH. Disorders in GSH related metabolism are
known to produce hemolysis (2). Anaemia in chronic
renal failure (CRF) is a common manifestation and it
has been described as normocytic and normochromic
(4). Deficiency of erythropoietin (5), and a hypoporoliferative bone marrow appear to be the principal
factors of the anaemia (6).
The biochemical alterations involved in this event
have not yet been completely clarified. Different mechanisms have been implicated in lysis of erythrocytes. It

different from the control group. But postdialysis plasma GSH levels increased from
predialysis levels (p<0.01). Plasma Selenyum
(Se) concentrations were lower in patients
than in controls (p<0.01) and not significantly changed with dialysis.
These results suggest that the anti-oxidant
system related to GSH is insufficient in CRF
patients and this system improves only partly
after hemodialysis.
Key Words: Glutathione, Glutathione peroxidase,
Glucose
6-Phosphate
dehydrogenase, Hemodialysis

has been claimed that CRF leads to a lipoperoxidative
process. The evidence consistly mostly of the detection
of breakdown products of lipid peroxides such as malonaldehyde (7). While data regarding the antioxidant
enzyme superoxides dismutase, catalase, and GPX are
contradictory (8-11). A changed erythrocyte membrane
fluidity (12) impairment of the Na-K pump in the
erythrocytes (13) could contribute to hemolytic anaemia in CRF.
Our previous study showed a decrease of glutathione related scavenger systems of oxygen radicals
in CRF patients (14). This study was therefore designed to examine the effect of hemodialysis on glutathione levels, GPX activities in plasma and erythrocytes, and the G-6-PD activities in erythrocytes of
patients with CRF.
Material and Methods
Thirty six patients with CRF (20 men, 16 women
aged 37±11 years) and 25 (15 men, 10 women) agematched healty colunteers were studied. The patients
had been on maintenance hemodialysis three times a
week for 2-5 years. The dialysate had the following
composition: Sodium 142 mEq/L, potassium 2mEq/L,
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calcium 3.5 mEq/L, magneisum 1.5 mEq/L, chloride
117 mEq/L, bicarbonate 30 mEq/L, acetic acid 2 mEq/
L. The dializers were equipped with a cuprophane fiber dialyzer membrane. The patients were not on any
drug therapies (vitamin E, vitamin D, erythropoietin,
Se, etc.) The patients had low Hb and Htc levels and
high urea nitrogen and creatinine levels (Table 1) Pre
and post hemodialysis blood samples were collected
into two tubes one of with EDTA for GPX assay and
the other with ACD for G-6-PD, glutathione assays.
Informed consent for entry into the study was obtained from all patients and volunteers.
Table 1.

Uremic and hematological parameters of the patients

Reference range

Hemodialysis
patients (mean±SD)

Creatinine (mg/dl)
Urea nitrogen (mg/dl)

0.5 - 1.6
8 - 22

Hb (g/dl)

12 - 16

Hct (%)

37 - 54

12.9 ± 0.4
96

±

±

All data were expressed as the mean values SD.
Data were analysed using student’s test.
Results
The activity of GPX, G-6-PD and the GSH content
of controls and patients are shown in Table 2 and 3.
Erythrocytes GSH concentrations were significantly
decreased in the pre-and postdialysis samples. Predialysis plasma GSH levels were not different from
controls. After dialysis, plasma and erythrocytes GSH
levels significantly increased compared with predialysis
levels. Erythrocytes and plasma GPX activities were
significantly lower in patients (pre and postdialysis)
than in controls. Also erythrocytes G-6-PD activities
were low. G-6-PD and GPx activities were significantly
increased by dialysis. Plasma Se concentrations were
significantly lower in pre and postdialysis samples than
controls (p<0.01) and not changed with dialysis.

5

7.6 ± 1.9
24

alytical grade and were purchased from the Sigma
chemical company (USA).

Table 2.

6

Blood samples were centrifuged at 2000 g. for 5
min. at 4ºC and the plasma were removed from the
packed RBC. The remaining red cells were washed
three times with 0.9 % NaCl and suspended in the
same solution to yield hemotocrit values of 70 %.
Plasma and erythrocytes GSH were measured using
Tietze method (15), GPX activities were determined
by Pleban et al. Method (16). The principle of GPX
activity is based on the decrease in NADPH absorbance
at 340 nm. By measuring the absorbance change per
min of NADPH, GPX activity of erythrocytes were expressed in U/g Hb of hemolysate. Erythrocytes G-6-PD
activities were measured using Sigma UV kinetic assay
(Cat No: 345-A).
The reaction catalyzed by G-6-PD was as follows
G-6-PD
G-6-P + NADP+
6-phosphogluconate +

Control
Predialysis
Postdialysis

Erythrocyte GPX (U/g Hb), G-6-PD (U/g Hb) activities and
GSH (µg/ml) levels of patients and controls

n

G-6-PD

GPX

25

5.4±0.2

26.1±4.9

a

a

36
36

76

a,b

4.1±0.2

363.6±23.2

20.2±4.2

231.4±19.1

a,b

21.2±4.5

a,b

294.6±22.3

a: p<0.01 from controls
b: p<0.01 from predialysis

Table 3.

Control

Plasma GPX (U/dL) activity and GSH (µg/ml), Se (µg/L)
concentrations of patients and controls

n

GPX

25

32.6±4.3
a

Predialysis

36

19.7±4.4

Postdialysis

36

21.1±4.2

+

NADPH + H . The enzyme activity is determined by
measurement of the rate of increase in NADPH concentration. Plasma Se concentrations were determined
by Jacopson and Lockitch method (17) using Hitachi
Z-8000 atomic absorption spectrophotometer graphite
furnace. The reagents and enzymes used were of an-

3.3±0.2

GSH

a: p<0.01 from controls
b: p<0.01 from predialysis

ab

GSH

Se

2.35±0.13

101.8±8.6

2.29±0.15

77.4±8.8

b

2.38±0.12

a
a

76.6±9.5
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Discussion
Glutathione is involved in a wide variety of biological reactions such as the maintenance of protein
thiol groups (-SH) in the reduced state, removal of
hydrogen peroxide, amino acid transport, detoxification of xenobiotics (18,19). It is likely that
GSH, a cofactor for GPX, could also be involveld in
the reduction of oxygen radicals as a free radical scavenger (9). Intracellular GSH is converted to oxidized
glutathione (GSSG) by GPX, which catalyzed the reduction lof the peroxides whose substrate is NADPH
and G-6-PD as a source of NADPH quarantee the reduction of GSSG for the maintenance pool of GSH
(2,19).
Our study showed that the patients with CRF had
low erythrocyte GSH levels but normal plasma GSH
levels. Also our previous results showed that the
GSSG/GSH ratio in erythrocytes and plasma were
higher in CRF patients than in controls (14). There
are conflicting results on GSH levels of hemodialysis
patients. Some authors reported high (1,20) and
some reported low (8-10,21,22) GSH levels of erytrocytes in CRF patients. In agreement with our
studies Vanella et al (8) found low GSH content in
erythrocytes of uremic patients before dialysis and
GSH levels were significantly increased after hemodialysis. But Chaunhan et al (10) suggest that there
was a decrease in red cell GSH after hemodialysis.
They did could not explain this result since their G-6PD levels of patients were low and after adequate dialysis or renal transplantation the G-6-PD values returned to normal.
We determined low G-6-PD and GPx activity in
erythrocytes of our patients and after dialysis. These
values were more elevated than predialysis. These results supported our increased GSH levels after dialysis.
It has been reported that plasma of uremic patients shows an inhibitory effects towards G-6-PD of
normal erythrocytes. Also the increase of G-6-PD values after hemodialysis may suggest that the G-6-PD
deficiency in uremic subjects may be reversible by appropriate treatment (23).
This condition and our results suggest that decreased GSH level in erythrocyte is due to the decreased availability of NADPH by decreased G-6-PD
activities. We observed erythrocyte and plasma low
GPX activities. These alterations may be related to Se

deficiency because we demonstrated low plasma Se
levels in patients. Se deficiency decreases GPX activity
(3,11,24). In contrast to our results Turi et al. (22)
found a decreased GPX activity with hemoldialysis (6
CRP patients). They suggest that decreased antioxidant
enzyme activity and GSH content may be the result of
the accumulation of RBC metabolites and uraemic toxins. This was not improved by dialysis, which may be
related to the non-dialysable character of these toxic
substances. Also they stated that there was an increased oxidatic stress in uraemic patients treated with
chronic hemodialysis. However, our findings are in accordance with some other (24,26). Saint Georges et al
(26) reported that plasma Se, GPX and erythrocyte
GPX activity were lower in hemodialyzed patients than
controls. After Se treatment of patients plasma GPX
activity increased to a plateau but remained lower
than in controls. Erythrocyte GPX activity rose progressively and then stabilized at the control levels. In
our study plasma Se did not significantly change during dialysis but GPX activity significantly elevated with
dialysis. These result may suggest that the mdecrease
of GPX activity in erythrocyte and plasma not only related to Se deficiency but could also be related to the
accumulation of metabolites and toxins in the blood inhibiting the GPX activity and enzymatic system such as
G-6-PD. These differences may be related to the hemodialysis years of the patients or the type of hemodialysis membrane and/or dialysate, or major minor
contributinos to numerous clinical manifestations associated with CRF and dialysis. The decrease of G-6PD, GPx activity and GSH content observed in erythrocytes of uremic patients may be related to the accumulation in metabolites and toxins inhibiting the enzymatic system of GSH metabolism. The deplation of
the scavenger system for oxygen free radicals makes
the uremic erythrocytes more vulnerable to oxidative
damage and may contribute, in part, to anaemia in
the uremic patients. Further studies will be necessary
on antioxidant mechanism in hemodialysis patients.
Oxidative haemolysis seems to be a mutifactorial
abnormality caused by a reduced level of GSH regeneration due to a defect (G-6-PD) of hexose monophosphate and a decreased antioxidant enzyme activity.
In conclusion the anti-oxidant system related to
GSH are insufficient in CRP patients who are on hemodialysis treatment and this system improves only
partly after hemodialysis.
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